Senzime AB (OTCPK:SNZZF)
$ 0.527 0 (0%) Market Cap: 68.54 Mil Enterprise Value: 66.06 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 59/100

Q3 2024 Senzime AB (publ) Earnings Call Transcript

Nov 06, 2024 / 02:00PM GMT
Release Date Price: $0.599
Operator

Welcome to Carnegie and this Q3 report presentation with Senzime.

My name is Klas Palin and I'm an equity analyst and have coverage of Senzime and I will be responsible for the Q&A session. But before that, we will listen to a company presentation and a presentation of the development in Q3, which will be held by CEO Philip Siberg.

Philip, very welcome. And please you may start your presentation.

Philip Siberg;publ;Chief Executive Officer
Senzime AB

()-

Okay. And thank you for listening to this quarterly Q3 report 2024. Okay. So Senzime, quick recap, I mean, we're a medical device company. We develop solutions to radically change and improve anaesthesia practice. So it's about helping patients throughout their journey from preoperative care and making sure they get the right dose of anaesthetic drugs and are excavated so they can wake up at the right time.

Our business is in around the Tegra system which is our predominant focus area. The Tegra system is used in thousands of operating rooms around

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot